GlassScriptPhysician profile
Jessica Wilson
NPI 1073924742
$2,325.38
in general payments reported to CMS, 2019-2025
28 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $25.80 · 2021: $226 · 2022: $258 · 2023: $92.58 · 2024: $631 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645 · Education: $46.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.99 |
| Education | $46.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $282.35 | 2024-2025 | |
| Lilly USA, LLC | $228.54 | 2021-2025 | Jardiance, Emgality, Zepbound |
| Novo Nordisk INC | $196.34 | 2019-2024 | Rybelsus, Ozempic |
| Amgen INC. | $156.31 | 2019-2024 | Tezspire, Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $151.75 | 2024-2025 | Takhzyro, Glassia, Hyqvia |
| Dexcom, INC. | $119.72 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $116.58 | 2022-2025 | Breztri, Farxiga, Fasenra |
| Galderma Laboratories, L.P. | $114.29 | 2025 | Nemluvio |
| Genentech USA, INC. | $111.44 | 2025 | Xolair |
| Exact Sciences Corporation | $106.97 | 2024-2025 | Cologuard Collection Kit |
| Pharming Healthcare, INC. | $103.80 | 2024-2025 | Ruconest |
| Pfizer INC. | $93.40 | 2019-2025 | |
| Csl Behring | $70.98 | 2024-2025 | Haegarda, Andembry |
| Invivyd INC | $63.79 | 2024-2025 | Pemgarda |
| Optinose US, INC. | $46.74 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $46.23 | 2025 | Xolair |
| Glaxosmithkline, LLC. | $46.03 | 2019-2023 | Shingrix |
| Allergan, INC. | $43.64 | 2019-2020 | |
| Abbvie INC. | $42.35 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.98 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $25.69 | 2022 | |
| Nevro Corp. | $24.35 | 2022 | |
| Cycle Pharmaceuticals INC | $22.29 | 2025 | Sajazir |
| Amarin Pharma, INC. | $21.88 | 2021 | |
| Aytu Biopharma, INC. | $18.80 | 2024 | Karbinal |
| Organon LLC | $15.45 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.87 | 2022 | |
| Sanofi Pasteur INC. | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.